Komori
Semiannual Report4539NIPPON CHEMIPHAR CO.,LTD.Pharmaceuticals

Semiannual Report — FY2026 H1

What NIPPON CHEMIPHAR CO.,LTD. reported for the period from 2026-04-01 to 2027-03-31.

How much it says
62Detailed
What moved here
11named for the first time
Its own wording
15terms
Which filing this is
38/ 38newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist

During the interim consolidated accounting period, sales, driven mainly by the pharmaceutical business (prescription drugs and clinical diagnostic reagents), came to ¥15,821 million, while the Company reported an operating loss of ¥696 million and an interim net loss attributable to owners of the parent of ¥512 million. In September, it launched the A-2 measuring instrument and KR-1 reagent for the “DropScreen” allergy screening equipment and reagents.

Komori's summary of this document, not the document's own words.
62Detailed
How much this filing saysA weighted roll-up of 10 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 37 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
73
Detailed
Magnitude of change
68
Detailed
Strategic shift
49
Typical
Capital movement
75
Very detailed
Disclosure gaps
53
Typical
Risk changes
55
Typical
Finance and capital policy
62
Detailed
Specificity of disclosure
53
Typical
Product portfolio
79
Very detailed
Technology position
50
Typical
Confidence in strategic bets
R&D spend12億円Money spent making new things.
Cash left over16億円Cash from the business, less what went into equipment.
Spent on equipment5億円Plants, machines — things meant to last.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.
NIPPON CHEMIPHAR CO.,LTD. — FY2026 H1 | Komori